Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
EuroEyes International Eye Clinic Limited (1846.HK)
Hamburg, CQ, HK
EuroEyes International Eye Clinic Limited provides vision correction services in Germany, the People’s Republic of China, Denmark, and the United Kingdom. The company offers laser eye surgery in various options, including SMILE Pro, Femto-Lasik, PRK, and Lasek; refractive laser surgery, such as ReLEx SMILE, Femto LASIK, and Presbyond; lens exchange surgery comprising monofocal and trifocal lens exchange surgery; and PRK/LASEK and ICRS implantation services. It also sells pharmaceutical products; rental of ophthalmic equipment and operating spaces; and provides training service. In addition, the company is involved in the operation of consultation centers and/or clinics for eye treatment, as well as LASIK centers; and trading of eye clinic equipment and lenses. EuroEyes International Eye Clinic Limited was founded in 1993 and is headquartered in Hamburg, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.77% | -2.96% | -11.49% | -17.61% | -13.82% | -10.27% | -46.53% | -76.94% | -76.18% | -76.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+11.2% ★ Q4'25: +13.9% (vs Q4'23)
-
EPS growth Medical - Care Facilities: +19.2%-32.0% Q4'25: -73.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+7.3% Q4'25: +18.6% (vs Q4'23)
-
EBIT margin Medical - Care Facilities: +11.3%+14.6% ★ Q4'25: +11.7% (vs Q4'23)
-
ROIC Medical - Care Facilities: +6.8%+7.0% ★ Q4'25: +11.8% (vs Q4'23)
-
Share dilution Medical - Care Facilities: +0.0%-3.2% ★ Q4'25: -3.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×2.51× ★ Q4'25: 1.47× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
427.20M
est: 433.74M (-1.5%)
|
473.82M
est: 477.08M (-0.7%)
|
632.93M
est: 632.22M (+0.1%)
|
610.29M
est: 823.11M (-25.9%)
|
714.29M
est: 736.28M (-3.0%)
|
715.68M
est: 744.54M (-3.9%)
|
796.04M
est: 798.00M (-0.2%)
|
1.13B
1.13B – 1.13B
+41.1% YoY
|
| EBITDA |
95.33M
est: 154.00M (-38.1%)
|
173.62M
est: 65.55M (+164.9%)
|
278.80M
est: 78.85M (+253.6%)
|
220.44M
est: 125.20M (+76.1%)
|
292.10M
est: 237.74M (+22.9%)
|
141.89M
est: 262.28M (-45.9%)
|
163.64M
est: 257.67M (-36.5%)
|
363.61M
363.61M – 363.61M
+41.1% YoY
|
| EBIT |
28.70M
est: 104.86M (-72.6%)
|
105.65M
est: 22.85M (+362.5%)
|
203.16M
est: 27.48M (+639.3%)
|
139.72M
est: 43.63M (+220.2%)
|
204.75M
est: 166.52M (+23.0%)
|
104.72M
est: 129.90M (-19.4%)
|
116.51M
est: 180.48M (-35.4%)
|
254.68M
254.68M – 254.68M
+41.1% YoY
|
| Net Income |
-3.66M
est: 376.03M (-101.0%)
|
65.58M
est: -2.58M (+2,638.9%)
|
133.56M
est: -3.11M (+4,398.8%)
|
89.47M
est: 110.42M (-19.0%)
|
131.24M
est: 104.04M (+26.1%)
|
82.29M
est: 89.55M (-8.1%)
|
54.45M
est: 105.54M (-48.4%)
|
118.33M
118.33M – 118.33M
+12.1% YoY
|
| SGA |
147.44M
est: 69.41M (+112.4%)
|
70.43M
est: 71.50M (-1.5%)
|
82.22M
est: 86.00M (-4.4%)
|
77.89M
est: 136.57M (-43.0%)
|
95.98M
est: 134.69M (-28.7%)
|
185.82M
est: 136.21M (+36.4%)
|
209.48M
est: 145.99M (+43.5%)
|
206.01M
206.01M – 206.01M
+41.1% YoY
|
| EPS |
-0.01
est: 1.14 (-101.3%)
|
0.20
est: 0.18 (+9.0%)
|
0.41
est: 0.41 (+0.0%)
|
0.27
est: 0.49 (-44.3%)
|
0.40
est: 0.33 (+23.0%)
|
0.25
est: 0.28 (-10.7%)
|
0.17
est: 0.33 (-48.5%)
|
0.37
0.37 – 0.37
+12.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daniel Zoltan Reinstein | Executive Director | 7M | — |
| Jörn Slot Jörgensen | Founder, Chief Executive Officer & Executive Chairman | 3M | — |
| Jannik Jonas-Slot Jørgensen | Vice President of Denmark & Executive Director | 2M | male |
| Marcus Huascar Bracklo | Executive Director & Chief Financial Officer | 1M | male |
| Michael Christian Knorz | Chief Medical Officer | — | — |
| Rosenna | Company Secretary | — | female |
| Jörg Matthia Hassel | Senior Consultant of Operations | — | male |
| Keith Nicholas Mckay | Senior Vice President of Operations (Germany) | — | male |
| Lars Jannik Boberg-Ans | Senior Vice President of Denmark | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1846.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
